JPMorgan discloses 6.3% Neurocrine stake in 13G/A filing (NBIX)

Rhea-AI Filing Summary

JPMorgan Chase & Co. filed an amended Schedule 13G reporting its beneficial ownership in Neurocrine Biosciences, Inc. common stock. JPMorgan reports beneficial ownership of 6,338,240 shares, representing 6.3% of the class of Neurocrine’s common stock, $0.001 par value.

Within this position, JPMorgan has sole voting powershared voting powersole dispositive powershared dispositive power

Key Figures

Beneficial ownership: 6,338,240 shares Percent of class: 6.3% Sole voting power: 5,719,691 shares +4 more

7 metrics

Beneficial ownership 6,338,240 shares Total Neurocrine Biosciences common shares beneficially owned by JPMorgan Chase & Co.

Percent of class 6.3% Percentage of Neurocrine Biosciences common stock class beneficially owned by JPMorgan

Sole voting power 5,719,691 shares Shares of Neurocrine common stock over which JPMorgan has sole voting power

Shared voting power 20,413 shares Shares of Neurocrine common stock over which JPMorgan has shared voting power

Sole dispositive power 6,337,388 shares Shares of Neurocrine common stock over which JPMorgan has sole dispositive power

Shared dispositive power 767 shares Shares of Neurocrine common stock over which JPMorgan has shared dispositive power

Filing date signature 07/27/2026 Date signed by Vice President Rachel Tsvaygoft on behalf of JPMorgan Chase & Co.

Key Terms

beneficially owned, sole voting power, shared dispositive power, Schedule 13G, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: 6338240 (b) | Percent of class: 6.3 %"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Number of shares as to which the person has | (i) Sole power to vote"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

shared dispositive power financial

"(iv) Shared power to dispose or to direct the disposition of: 767"

Schedule 13G regulatory

"Ownership of more than 5 Percent on Behalf of Another Person. | If any other person"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

investment company registered under the Investment Company Act of 1940 regulatory

"A listing of the shareholders of an investment company registered under the Investment Company Act"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/27/2026 - 11:17 AM Accepted by SEC EDGAR 07/27/2026 - 11:17 AM Learn about SEC filing dates

FAQ

What percentage of Neurocrine Biosciences (NBIX) does JPMorgan Chase & Co. report owning?

JPMorgan Chase & Co. reports beneficial ownership of 6.3% of the class of Neurocrine Biosciences common stock. This corresponds to 6,338,240 shares of NBIX common stock, as disclosed in the Schedule 13G/A filing.

How many Neurocrine Biosciences (NBIX) shares does JPMorgan beneficially own according to this Schedule 13G/A?

JPMorgan Chase & Co. reports 6,338,240 shares of Neurocrine Biosciences common stock as beneficially owned. This position represents 6.3% of the outstanding class of NBIX common stock, based on the figures disclosed.

What voting power does JPMorgan have over its Neurocrine Biosciences (NBIX) shares?

JPMorgan has sole voting power over 5,719,691 shares and shared voting power over 20,413 shares of Neurocrine Biosciences common stock. These figures outline how many NBIX shares JPMorgan can vote independently or jointly.

What dispositive power does JPMorgan report over Neurocrine Biosciences (NBIX) shares?

JPMorgan reports sole dispositive power over 6,337,388 shares and shared dispositive power over 767 shares of Neurocrine Biosciences common stock. Dispositive power reflects authority to decide whether to sell or otherwise dispose of the NBIX shares.

Which JPMorgan subsidiaries are involved in holding Neurocrine Biosciences (NBIX) shares?

The filing lists multiple JPMorgan entities, including J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank, National Association, and several JPMorgan Asset Management affiliates, as subsidiaries associated with the reported NBIX holdings.

Does any other person have more than 5% economic interest in Neurocrine Biosciences (NBIX) through JPMorgan’s holdings?

The filing states “Not Applicable” for ownership of more than 5 percent on behalf of another person. This indicates no separately identified person is disclosed as having dividend or sale proceeds rights exceeding 5% of the NBIX class through these holdings.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

NEUROCRINE BIOSCIENCES, INC.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

64125C109

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 64125C109

1

Names of Reporting Persons

JPMORGAN CHASE & CO.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,719,691.00
6	Shared Voting Power 20,413.00
7	Sole Dispositive Power 6,337,388.00
8	Shared Dispositive Power 767.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,338,240.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.3 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: NEUROCRINE BIOSCIENCES, INC.
(b)	Address of issuer's principal executive offices: 6027 Edgewood Bend Court San Diego CA 92130
Item 2.
(a)	Name of person filing: JPMORGAN CHASE & CO.
(b)	Address or principal business office or, if none, residence: 270 Park Avenue,,New York, NY 10017
(c)	Citizenship: DE
(d)	Title of class of securities: Common Stock, $0.001 par value
(e)	CUSIP No.: 64125C109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6338240
(b)	Percent of class: 6.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5719691
	(ii) Shared power to vote or to direct the vote: 20413
	(iii) Sole power to dispose or to direct the disposition of: 6337388
	(iv) Shared power to dispose or to direct the disposition of: 767
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. J.P. Morgan Trust Company of Delaware; J.P. Morgan Securities LLC; JPMorgan Asset Management (Asia Pacific) Limited; JPMorgan Asset Management (UK) Limited; JPMorgan Chase Bank, National Association; J.P. Morgan Investment Management Inc.; J.P. Morgan Mansart Management Limited; JPMorgan Asset Management (Japan) Limited; 55I, LLC
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. Not Applicable
Item 9.	Notice of Dissolution of Group.
	Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

JPMORGAN CHASE & CO.

Signature:	Rachel Tsvaygoft
Name/Title:	Vice President
Date:	07/27/2026